Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
Keyword(s):
Phase 3
◽
Abstract not available.
2019 ◽
Vol 81
(4)
◽
pp. AB202
2019 ◽
Vol 81
(4)
◽
pp. AB202
2018 ◽
Vol 79
(2)
◽
pp. 287-293
◽
2018 ◽
Vol 79
(3)
◽
pp. AB139